IRIX (IRIDEX) Interest Expense : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 1996. Start your Free Trial

What is IRIDEX Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. IRIDEX's interest expense for the three months ended in Dec. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. IRIDEX's Operating Income for the three months ended in Dec. 2024 was $ -0.50 Mil. IRIDEX's Interest Expense for the three months ended in Dec. 2024 was $ 0.00 Mil. GuruFocus does not calculate IRIDEX's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

IRIDEX Interest Expense Historical Data

The historical data trend for IRIDEX's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRIDEX Interest Expense Chart

IRIDEX Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

IRIDEX Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

IRIDEX Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

IRIDEX (NAS:IRIX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

IRIDEX's Interest Expense for the three months ended in Dec. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2024 was $-0.50 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was $1.82 Mil.

IRIDEX's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

GuruFocus does not calculate IRIDEX's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

IRIDEX Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IRIDEX Corp (NAS:IRIX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

1212 Terra Bella Avenue, Mountain View, CA, USA, 94043

Website

https://www.iridex.com

IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

Executives

Nandini Devi	director	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Beverly A Huss	director	C/O ACCURAY INCORPORATED, 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Earle Grove	director	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Topcon Corp	10 percent owner	75-1, HASUNUMA-CHO, ITABASHI-KU, TOKYO M0 174-8580
Topcon America Corp	10 percent owner	111 BAUER DRIVE, OAKLAND NJ 07426
Fuad Ahmad	officer: Interim CFO	461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Doris Engibous	director	C/O NATUS MEDICAL INCORPORATED, 1501 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Scott Shuda	director	402 RAILROAD AVENUE, SUITE 201, DANVILLE CA 94526
Patrick Mercer	officer: COO	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Maria Sainz	director	C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Ruediger Naumann-etienne	director
Robert A Gunst	director
David Bruce	director, officer: President and CEO	1178 GLEN ROAD, LAFAYETTE CA 94549
Ken Ludlum	director
Romeo R Dizon	other: Vice President and Controller	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043